This review focuses on patient care tips and practices for the care of patients with B-NHL or MM receiving bispecific antibody therapy.

A retrospective study suggests a high burden of prolonged, mostly low-grade infections in patients with multiple myeloma who receive T-cell-engaging therapies.

Izalontamab brengitecan (iza-bren) is an antibody-drug conjugate and bispecific antibody undergoing evaluation in small cell ...

T-cell therapy is the most efficacious approach for many patients with relapsed/refractory multiple myeloma, but it currently comes with 2 periods ...

Acute myeloid leukemia (AML) has a poor prognosis, especially in elderly and relapsed/refractory patients, with 5‑year ...

Myeloma is a cancer that affects specialised antibody-producing cells called plasma cells. Over your lifetime, your body ...

Trastuzumab pamirtecan, an investigational HER2-targeted antibody-drug conjugate, met the primary efficacy endpoint in a Phase 2 cohort of ...

A single-center real-world study compares the effectiveness and toxicity of chimeric antigen receptor T-cell therapy vs ...

High co-payments for potentially curative cell and gene therapies create avoidable access barriers; value-based insurance ...

Study Highlights Dagger® Technology Showing that an Optimized CD70 CAR has the Potential to Protect Against Immune Rejection, Enabling Robust ...

Car-T cell therapy is “borrowed” from cancer treatment. Image in Creative Commons. A 47-year-old woman in Germany had spent ...

Malaysia faces a critical shortage of trained haematologists as the burden of blood-related disorders continues to rise.